INTRODUCTION
Fabry disease is an X-linked heritable disorder of glycosphingolipid metabolism caused by the deficient activity of the lysosomal enzyme a-galactosidase A (GLA) (Online Mendelian Inheritance in Man 301499). 1 This disorder engenders progressive accumulation of glycosphingolipids such as globotriaosylceramide within tissues and organs, especially in the skin, nervous system, eye, heart and kidney. Typically in male hemizygotes, clinical manifestations caused by glycosphingolipid accumulation, such as acroparesthesias, hypohidrosis and corneal opacities, are observed during childhood. In the fourth or fifth decade of life, vascular involvement and subsequent cardiac hypertrophy and arrhythmia, proteinuria and renal dysfunctions, and brain stroke develop. 2,3 Recent reports have described atypical variants of Fabry disease that are limited to cardiac or renal involvement. [4] [5] [6] As they show no classical manifestation during childhood, several variant Fabry disease patients are presumably undiagnosed. Although renal biopsy is the gold standard for the diagnosis of kidney diseases, not all end-stage renal disease (ESRD) patients receive renal biopsy before induction of dialysis. Instead, clinical diagnoses, such as chronic glomerulonephritis, diabetic nephropathy and hypertensive nephrosclerosis, would be assigned to ESRD patients by physicians. Therefore, it is possible that undiagnosed Fabry disease patients can be found in ESRD patients with other diagnosis of kidney disease.
The clinical introduction of enzyme replacement therapy (ERT) with recombinant GLA in 2001 enables us to treat patients with Fabry disease more specifically. ERT is effective for alleviating neuropathic pain, hypertrophic cardiomyopathy and sweat dysfunction, and for stabilizing kidney function. [7] [8] [9] [10] [11] [12] This effectiveness encouraged us to proceed with screening studies of ESRD patients to identify Fabry patients who had never been suspected as having GLA deficiency. A systematic review by Linthorst et al. 13 described the prevalence of Fabry disease in male dialysis patients in 10 studies as 0.33% (95% confidence interval 0.20-0.47%). 13 To date, four screening studies for 1989 male Japanese dialysis patients have identified 12 Fabry patients (0.60% (95% confidence interval 0.26-0.94%)). [14] [15] [16] [17] Three of them used plasma GLA assaying as the screening method; [15] [16] [17] one employed a dried blood spot test. 14 This study was designed to identify undiagnosed renal Fabry patients among ESRD patients using a high-throughput screening system, which allowed us to measure GLA activity of serum samples distributed in 96-well plates within 4 h. We also measured GLA activity of peripheral leukocytes to confirm the diagnosis and to examine genetic mutations in the GLA gene (GLA) further.
MATERIALS AND METHODS

Study population
This study examined 1080 male ESRD patients who were treated by maintenance hemodialysis at 14 dialysis centers in Tokyo area, none of whom had been diagnosed previously as having Fabry disease. This study was approved by the Institutional Review Board (IRB) and the Ethics Committee for Human Genome Study in The University of Tokyo and Meiji Pharmaceutical University. As no dialysis center has its own IRB, IRB in The University of Tokyo reviewed the study protocol upon the request from each dialysis center. Written informed consent was obtained from each participant at the time of recruitment.
Measurement of serum and leukocyte GLA activity
Serum samples were obtained at the start of dialysis by immediate centrifuge (3000 r.p.m. Â 10 min) and kept at 4 1C for up to 24 h. Then serum samples were further kept at À30 1C until GLA activity measurement. GLA activity was measured using a substrate solution containing 5 mmol l À1 4-methylumbelliferyl a-D-galactopyranoside (Calbiochem, La Jolla, CA, USA) as a substrate and 117 mmol l À1 N-acetyl-D-galactosamine (Sigma-Aldrich Corp, St Louis, MO, USA) as a specific inhibitor of N-acetylgalactosaminidase in 0.1 mol l À1 citrate-phosphate butter, pH 4.6. 18 In the first screening, 20 ml of serum was mixed with 40 ml of the substrate solution in a 96-well plate. The mixture was incubated at 37 1C for 4 h. Then the reaction was stopped by adding 200 ml of 0.2 mol l À1 glycine buffer, pH 10.7, and the released 4-methylumbelliferone was measured using a Wallac 1420 ARVO MX Multilabel Counter (PerkinElmer Inc., Waltham, MA, USA) at excitation and emission wavelengths of 355 and 460 nm, respectively. When the serum GLA activity was lower than 1.5 nmol h À1 ml À1 , the leukocyte GLA activity was measured. In the second examination, 10 ml of leukocyte homogenate (10 mg protein) was mixed with 40 ml of the substrate solution in a 1.5-ml microtube. The mixture was incubated at 37 1C for 30 min. Then, the reaction was stopped by adding 950 ml of 0.2 mol l À1 glycine buffer, pH 10.7, and the released 4-methylumbelliferone was measured using a spectrofluorometer (F2700; Hitachi Ltd, Tokyo, Japan) at excitation and emission wavelengths of 365 and 450 nm, respectively.
Genome DNA analysis of the GLA gene Genomic DNA was purified from leukocytes with a Wizard Genomic DNA Purification Kit (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions. Seven exons of the GLA gene were amplified by PCR using appropriate primers. 19 The PCR protocol consists of 2 min at 94 1C, then 35 cycles of 15 s at 94 1C, 30 s at 55 1C, 40 s at 68 1C, and 1 min at 68 1C with KOD-plus DNA polymerase (Toyobo Co. Ltd, Osaka, Japan). The PCR fragment was directly sequenced.
Structural modeling of mutant GLA proteins
Structural modeling of mutant GLA proteins was performed using molecular modeling software TINKER, as described previously. 20 The crystal structure of human GLA (PDB: 1R46) was used as a template, and energy minimization was performed. The root-mean-square gradient value was set at 0.05 kcal mol À1 per Å´. Coloring of the affected atoms in the threedimensional structure of GLA was performed based on the distances between the wild-type and mutant ones.
RESULTS
Patients
This study examined 1080 male ESRD patients treated by maintenance hemodialysis at 14 dialysis centers in Tokyo area. The causes of ESRD described in the medical records were chronic glomerulonephritis (n ¼ 376, 34.8%), diabetic nephropathy (n ¼ 372, 34.4%), nephrosclerosis (n ¼ 140, 13.0%), polycystic kidney disease (n ¼ 47, 4.4%) and miscellaneous other conditions (n ¼ 54, 5.0%). Also, 91 patients (8.4%) were described as ESRD with unknown etiology. Their age was 63.4±13.0 (mean±s.d.) years at enrollment. They had started to receive dialysis at 55.1 ± 15.7 years.
Measurement of GLA activity A preliminary study was performed to determine the cutoff point of serum GLA activity in this study. The serum GLA activities of 32 apparently normal subjects and 54 Fabry patients who had already been diagnosed were, respectively, 4.6 ± 1.6 (mean ± s.d.) and 0.1 ± 0.1 nmol h À1 ml À1 . Considering the result (mean À2 s.d. ¼ 1.4 nmol h À1 ml À1 ), we determined the cutoff point as 1.5 nmol h À1 ml À1 to avoid a false-negative case. Analysis with these 86 individuals revealed that this cutoff point provided highly accurate diagnosis of Fabry disease (sensitivity 100%, specificity 100%) (Figure 1) . Figure 2 shows the distribution of serum GLA activity in the enrolled ESRD patients. The first screening revealed that the average of GLA activity of all the subjects was 4.6±1.3 nmol h À1 ml À1 ; 10 of the subjects showed enzyme activity lower than 1.5 nmol h À1 ml À1 . Leukocyte GLA activity in these 10 patients was subsequently measured to confirm the Fabry disease diagnosis (Table 1 ). The average of leukocyte GLA activity of 33 apparently normal subjects was 49 ± 20 nmol h À1 per mg protein. Two patients exhibited remarkably low GLA activity and were diagnosed as having Fabry disease (Cases 1 and 2). Notably, they were diagnosed as ESRD because of chronic glomerulonephritis when they started dialysis therapy. Case 1 was complicated with severe hypertrophic cardiomyopathy and arrhythmia (frequent premature ventricular contraction). Magnetic resonance imaging of the brain revealed multiple infarction. One brother died suddenly at the age of 37 years; another brother suffered from sick sinus syndrome. Case 2 was complicated with moderate left ventricular hypertrophy, but had no remarkable family history (Figure 3 ). None of these two patients showed any typical symptoms of classical Fabry disease, such as abnormal sweating, angiokeratoma and cornea verticillata. Eight other patients had residual enzyme activity of about 24-65% of the normal control mean (Cases 3-10).
Identification of gene mutation in GLA gene Direct sequencing was conducted on all the exons of the GLA gene with the genomic DNA of the 10 patients who were selected by the 
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K Doi et al first screening (Table 1 and Figure 4) . A missense mutation of p.G195V was found in Case 1. Case 2 had another missence mutation of p.M296I. These had been identified in several patients with variant form of Fabry disease. 4, 17, 21 The others (Cases 3-10) had a p.E66Q allele that had been reported previously as a functional polymorphism (rs28935191). 22 Notably, serum GLA activity of these p.E66Q patients were higher than the p.G195V and p.M296I patients ( Figure 5 ).
Prediction of structural changes caused by amino-acid substitutions
We constructed three-dimensional models of the GLA proteins with amino-acid substitutions attributable to p.G195V, p.M296I and p.E66Q. Coloring of the atoms affected by the amino-acid substitutions is shown in Supplementary Figure 6 (Supplementary information is available at Journal of Human Genetics' website at the end of the article and before the references). In these cases, the predicted structural changes caused by the amino-acid substitutions are small and are localized on the molecular surface far from the active site.
DISCUSSION
We conducted large-scale screening of Fabry disease with 1080 Japanese male ESRD patients using a high-throughput measurement of serum GLA activity followed by leukocyte GLA assaying, and successfully identified two disease-causing mutants and eight functional variants of the GLA gene. In the first screening of serum GLA measurement, 10 patients showed low GLA activity. The second test of leukocyte enzyme assay confirmed the diagnosis of Fabry disease with two patients whose GLA activity was almost deficient. They had genetic mutations of p.G195V in exon 4 and p.M296I in exon 6, which were identified in some patients with variant form of Fabry disease exhibiting renal or cardiac involvement. 4,17,21
The incidence of classic Fabry disease has been estimated as 1 in 50 000 males. 23 Dutch metabolic diagnostic centers reported birth prevalence of 1 in 238 000 in male newborns. 24 However, Spada et al. 25 found high incidence of later-onset Fabry disease (that is, cardiac and renal variants) by newborn screening. They reported that the incidence of GLA deficiency was about 1 in 3100, with an 11:1 ratio of patients with the variant: classic phenotypes. However, the results of screening studies of 'high risk' populations such as ESRD and hypertrophic cardiomyopathy showed higher incidence. 13 The calculated prevalence of Fabry disease in this study was lower than that reported in previous studies that examined Japanese dialysis patients (0.19 vs 0.60%). [14] [15] [16] [17] The difference is probably derived from the diagnostic criteria of Fabry disease. It should be addressed that previous studies included subjects with the p.E66Q allele as a 'renal variant' of Fabry disease. 14, 15, 17, 26 However, Lee et al. 22 reported that the allele A g ea te n r o l l m e n t( y e a r ) 5 5 6 1 4 5 8 3 7 6 7 0 7 6 6 7 7 6 8 0 frequency of p.E66Q in Korean individuals was remarkably higher (1.046% (95% confidence interval, 0.458-1.634%)) than the prevalence of Fabry disease. They also demonstrated that p.E66Q was a functional polymorphism rather than a pathogenic mutation using COS-7 cells overexpressing a-GLA harboring p.E66Q. More recently, we clearly demonstrated that p.E66Q was a functional variant and could be false negatively identified as Fabry disease because of its instability. 27 Biochemical, pathological and structural studies revealed subjects harboring the p.E66Q exhibited relatively high residual enzyme activity in white blood cells as also shown in this study, and that there was no accumulation of globotriaosylceramide in cultured fibroblasts or an increased level of plasma globotriaosylsphingosine in these subjects. Of note, we also demonstrated the GLA enzyme in plasma from subjects harboring the p.E66Q enzyme decreased after incubation for 4 h at 37 1C, indicating the GLA with the E66Q amino-acid-substitution is more unstable and therefore the p.E66Q subject can be false positively detected as Fabry disease. 27 On the other hand, the first screening using serum samples in the present study detected relatively but significantly higher GLA activity in eight p.E66Q patients than two disease-causing mutants (Table 1, Figure 5 ). Although the values were lower than the cutoff (1.5 nmol h À1 ml À1 ), this result indicates that serum assay of GLA activity can distinguish functional polymorphisms including p.E66Q from pathogenic mutations when a proper cutoff value is determined. It must be stated that not all the p.E66Q patients were identified in this study, because genetic analysis was conducted in only 10 patients who showed low-serum GLA activity. In addition, only two Fabry disease patients (positive control) were identified in this study.
Further investigation with larger sample size is necessary to confirm the performance of serum GLA activity measurement as a screening method for Fabry disease. To date, more than 500 mutations have been identified in the GLA gene. 28 In this study, two disease-causing mutations of p.G195V and p.M296I were identified. The predicted structural change in this mutant protein is small and is located on the molecular surface far from the active site. The degree of structural change in these mutants is not large compared with that in the case of p.E66Q. However, even such minor conformational change is expected to be detected by the endoplasmic reticulum's quality control system and the mutant GLA proteins might be degraded before transportation to lysosomes in these mutants, although subjects having these mutant alleles exhibit a mild phenotype of Fabry disease. 20, 29 As described above, Fabry patients of variant type lack specific symptoms in childhood and show variable clinical expression at later time points. Therefore, such patients would be misdiagnosed and would lose the opportunity of receiving ERT, which is expected to be especially effective in less severely affected Fabry patients. ERT was not able to stabilize renal function in chronic kidney disease patients with severe proteinuria or a glomerular filtration rate of lower than 60 ml min À1 . 30 This study aimed at finding undiagnosed Fabry patients who were suffering from ESRD. Although ERT might not reverse far advanced renal failure, dialysis patients will have some benefits. ESRD patients are very frequently complicated with severe cardiovascular diseases. 31 Figure 4 Genetic analysis of GLA gene. Genomic DNA was isolated from leukocytes and a genetic analysis was performed by direct sequencing (p.G195V (left), p.M296I (center) and p.E66Q (right)). 
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In conclusion, two undiagnosed variant type of Fabry patients and eight subjects with a functional polymorphism were identified in male Japanese hemodialysis patients using our high-throughput serum screening. Serum GLA activity was able to distinguish disease-causing mutants from a functional polymorphism (p.E66Q). Our result addressed the high prevalence of undiagnosed Fabry patients in ESRD population and the necessity of better strategy for finding variant Fabry patients in the stage, when they would have a benefit by ERT.
